Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65  years: a real-life multicentre analysis of 162 patients

ConclusionsAnti-CGRP mAbs are safe and effective treatments in migraine patients over 65  years old in real-life clinical practice.Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research